Relay Therapeutics adopts exclusive federal forum for securities claims

Relay Therapeutics, Inc.

Board approved second amended and restated bylaws effective March 6, 2026.
New exclusive forum provision requires securities law claims to be brought in federal district courts unless company consents otherwise.
Amendment covers claims under Securities Act of 1933 and Exchange Act of 1934.
No other material changes to bylaws were disclosed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Relay Therapeutics, Inc.: Amended and restated bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims (effective 2026-03-06).

Change: bylaw amendment
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, the Board of Directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (the “A&R Bylaws”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-102178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.